10-Q: Sunshine Biopharma Q3 2026: Revenue Dip, Net Loss Widens

Sunshine Biopharma Inc. reported a slight revenue decrease and a wider net loss for the nine months ended September 30, 2026, while highlighting progress in proprietary drug development and significant cash inflows from financing activities.

Summary

• For the nine months ended September 30, 2026, Sunshine Biopharma Inc. reported revenues of $26,794,777, a decrease from $27,728,750 in the same period of 2025.
• The cost of sales increased to 71.2% of revenue in the 2026 period, leading to a gross profit of $7,709,374, down from $9,226,832 in 2025.
• General and administrative expenses decreased to $12,008,321 in the nine months of 2026 from $13,663,850 in 2025, largely due to a significant impairment of intangible assets in the prior year.
• The company incurred an operating loss of $4,298,947 for the nine months ended September 30, 2026, compared to $4,437,018 in the prior year.
• Net loss for the nine months ended September 30, 2026, was $4,031,857, an increase from $3,834,425 in the same period of 2025.
• Cash and cash equivalents stood at $14,618,614 as of September 30, 2026.
• Net cash used in operating activities was $4,374,080 for the nine months of 2026.
• Financing activities provided $10,036,080 in cash for the nine months of 2026, up from $4,023,908 in 2025, primarily due to a public offering.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to declining revenues, increased net loss, and ongoing need for capital, despite progress in R&D and positive cash flow from financing.

Positives

• Cash and cash equivalents increased to $14,618,614 as of September 30, 2026, from $9,123,308 as of December 31, 2025.
• Significant cash inflow from financing activities, totaling $10,036,080 for the nine months ended September 30, 2026, driven by a public offering and warrant exercises.
• Progress in proprietary drug development, with K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections in animal testing stages.
• The company has 61 generic prescription drugs on the market in Canada and anticipates launching 4 additional drugs during the remainder of 2026.
• The company estimates its existing cash and projected sales will fund operations for the next 29 months.
• Disclosure of a U.S. patent (No. 12,624,066 B2) for compounds and methods for treatment of Coronavirus Infection, with an extended expiration date of 2043.
• The company's disclosure controls and procedures were deemed effective as of September 30, 2026.

Negatives

• Revenue for the nine months ended September 30, 2026, decreased by 3.4% to $26,794,777 compared to $27,728,750 in the same period of 2025.
• Gross profit decreased by $1,517,458 to $7,709,374 for the nine months ended September 30, 2026, from $9,226,832 in 2025, due to an increase in the cost of goods sold.
• Net loss for the nine months ended September 30, 2026, increased to $4,031,857 from $3,834,425 in the same period of 2025.
• Net cash used in operating activities increased by $627,426 to $4,374,080 for the nine months ended September 30, 2026, compared to the prior year.
• The company has no committed sources of capital and anticipates needing to raise additional capital in the future, with no assurance of availability on acceptable terms.
• The company experienced a $1,616,459 impairment of intangible assets during the nine months ended September 30, 2025, which did not recur in 2026, but this was offset by increased cost of sales.
• The company's basic loss per common share for the nine months ended September 30, 2026, was $(26.43), compared to $(195.37) in the prior year, indicating a wider loss on a per-share basis due to fewer shares outstanding after reverse splits.

Risks

• Generic drug prices in Canada are highly dependent on government policies and negotiations, which may change over time.
• The company has no committed sources of capital and anticipates needing to raise additional capital in the future, with no assurance that it will be available on terms acceptable to the company, or at all.
• The company maintains a full valuation allowance against its deferred tax assets and expects to maintain it until there is sufficient evidence of future taxable income, which is uncertain.
• The company is involved in a claim filed with the American Arbitration Association by its former legal counsel for unpaid compensation, which the company believes is without merit.
• The company's proprietary drug development programs are in early stages (animal testing) and subject to significant risks and uncertainties, including regulatory approval and market acceptance.
• The company's operations are primarily in Canada, making it subject to Canadian federal and provincial income taxes and regulatory environments.
• The company's ability to commercialize its proprietary drugs is dependent on successful research, development, clinical trials, and regulatory approvals.

Future Outlook

The company estimates its existing cash on hand and cash generated from sales will be sufficient to fund operations for the next 29 months. However, it anticipates the need to raise additional capital in the future for expansion and R&D, with no assurance of availability on acceptable terms.

Management Comments

• Management believes the addition of new products to their portfolio will strengthen their presence in the Canadian generic drug market and provide greater access to pharmacies.
• Management is focused on increasing sales and streamlining operations to reduce expenses.
• Management has evaluated the effectiveness of disclosure controls and procedures and concluded they were effective as of September 30, 2026.

Industry Context

StockSavvy.ai notes that the Canadian generic drug market is substantial ($11.2 billion annually per IMARC Group), and Sunshine Biopharma's strategy to expand its portfolio of 61 generic drugs and pipeline of 21 new drugs positions it to compete in this space. The recent extension of the 2023 Generic Drug Pricing Agreement for an additional two years, effective October 1, 2026, provides some pricing stability for the Canadian market.

Comparison to Industry Standards

• The company's revenue of approximately $9 million per quarter is modest compared to larger pharmaceutical companies, but it aims to grow its market share in the Canadian generic drug market.
• The company's gross profit margin of approximately 32.8% for the three months ended September 30, 2026, is within a typical range for generic pharmaceutical distributors, though cost of goods sold has increased.
• The company's net loss per share of $(26.43) for the nine months ended September 30, 2026, indicates a significant burn rate, which is common for early-stage pharmaceutical development companies but requires careful management and access to capital.

Legal Proceedings

• A claim has been filed with the American Arbitration Association by the attorneys of Andrew Telsey, former legal counsel, asserting unpaid compensation. The company believes the claim is without merit and intends to defend its position vigorously.

Related Party Transactions

• Of the officer compensation paid through September 30, 2026, $472,000 was paid to Advanomics Corporation, a company controlled by the CEO.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and the ongoing need for capital raises, which could dilute ownership.
• Employees may be affected by the company's focus on streamlining operations.
• Suppliers and creditors may be impacted by the company's financial performance and liquidity position.

Next Steps

• Continue to focus on increasing sales and streamlining operations to reduce expenses.
• Advance proprietary drug development programs (K1.1 mRNA and SBFM-PL4).
• Anticipate launching 4 additional generic drugs during the remainder of 2026.
• Seek additional capital for expansion and R&D.

Key Dates

Recommendation

The company shows progress in its R&D pipeline and has a stable base in the Canadian generic market. However, the declining revenue, widening net loss, and significant reliance on future capital raises present considerable risks. A 'hold' recommendation reflects a balance between potential upside from drug development and the current financial challenges.

Keywords

pharmaceutical, generic drugs, drug development, oncology, antiviral, mRNA, SARS Coronavirus, Canada